CD274 and hypothyroidism: Avelumab (Bavencio®) is a PD-L1 inhibitor from the IgG1 subclass, approved by the FDA in 2017 for urothelial carcinoma, Merkel cell carcinoma and renal cell carcinoma (13, 83), while inducing hypothyroidism as irAE (64).